Monoclonal antibodies directed against ndp-kinase
CA 2108533 C · Owner: Pulido-Cejudo, Gabriel · Inventors: Pulido-Cejudo, Gabriel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A monoclonal antibody against cytosolic nucleoside diphosphate kinase (NDP-kinase: EC 2.7.4.6) from HL60 cells has been produced. The monoclonal antibody solely recognizes the active oligomeric form of NDP-kinase and does not inhibit NDP-kinase activity. Reduction and alkylation of NDP-kinase oligomer performed under denaturing conditions fully destroyed the antigenic site recognized by the monoclonal antibody. Western blot analysis after non-denaturing polyacrylamide gel electrophoresis (PAGE) revealed that a single protein oligomer is recognized by the MAb. The protein band showed the same electrophoretic mobility of pure cytosolic NDP-kinase detected by a specific NDP-kinase enzymic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 15, 1993 and granted October 8, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 15, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 15, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.